Antithrombin III clinical trials
Also written Thrombate III and Atenativ.
Includes 1 study of Antithrombin-III.
How each study uses Antithrombin III is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Antithrombin III studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Dec 1991 · Thrombate Iii · BLA 103196 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 9
Universitaire Ziekenhuizen KU Leuven (1) · Seoul National University Hospital (1) · Duke University (1) · Grifols Therapeutics LLC (1) · Children's Hospital Medical Center, Cincinnati (1) · Instituto Grifols, S.A. (1) · The Hospital for Sick Children (1) · Octapharma (1)
Often tested with
Tested in the same studies.
Infliximab (1) · Apotransferrin (1) · Complement C1 Inhibitor Protein (1) · Glutathione (1) · Melatonin (1) · Epoprostenol (1) · Continuous Infusion Procedure (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Antithrombin III, phase 3 first.
- Dec 2026Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or DeliveryPhase 3 · Octapharma
Studies
Open first, then newest update. How each study uses Antithrombin III is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or DeliveryRecruitingPhase 3OctapharmaNCT04918173Written as Atenativ
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)CompletedPhase 2Universitaire Ziekenhuizen KU LeuvenNCT02251041Written as Antithrombin-III
- Antithrombin III in Infectious Disease Caused by COVID-19TerminatedPhase 2Enrique GinzburgNCT04899232Written as Antithrombin III
- Antithrombin III Concentrate After Liver TransplantationCompletedNot applicableSeoul National University HospitalNCT04219579Written as Antithrombin III, continuous infusion
- Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With CirrhosisWithdrawnPhase 1Jonathan StineNCT04055389Written as Antithrombin III
- Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac SurgeryCompletedPhase 2Duke UniversityNCT02103114Written as Anti-thrombin III
- Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary BypassCompletedPhase 2Grifols Therapeutics LLCNCT02037555Written as AT-III (Human)
- Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO SupportCompletedPhase 1Children's Hospital Medical Center, CincinnatiNCT02631174Written as Antithrombin III
- Atenativ Effect on Uterine Blood Flow and PreeclampsiaWithdrawnPhase 4Vastra Gotaland RegionNCT02278575Written as Atenativ
- Use of Antithrombin in Cardiac Surgery With Cardiopulmonary BypassCompletedPhase 2Instituto Grifols, S.A.NCT00823082Written as Antithrombin III
- Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac SurgeryCompletedPhase 3The Hospital for Sick ChildrenNCT01530737Written as Antithrombin III
- Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac SurgeryStatus unknownPhase 4University of BariNCT01201070Written as antithrombin III
Codes
What other systems call Antithrombin III · ClinicalTrials.gg INT007011
- MeSH (NLM) D000990Antithrombin IIIOne source ClinicalTrials.gov
- UNII (FDA) T0LTO7L82XANTITHROMBIN III HUMANOne source FDA
- RxNorm 221062One source FDA
- NCI Thesaurus C136824Therapeutic Human Antithrombin-IIIOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000990 | Antithrombin III | One source ClinicalTrials.gov |
| UNII (FDA) | T0LTO7L82X | ANTITHROMBIN III HUMAN | One source FDA |
| RxNorm | 221062 | — | One source FDA |
| NCI Thesaurus | C136824 | Therapeutic Human Antithrombin-III | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.